The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InCellectar Biosciences has officially enrolled the first patient in its Phase 1b clinical trial evaluating CLR 125 for the treatment of refractory triple-negative breast cancer (TNBC). The investigational drug utilizes innovative Auger-emitting radioconjugate technology designed to target aggressive cancer cells. This trial is structured to assess the safety, tolerability, and preliminary efficacy of the treatment across three distinct dose levels. The commencement of this study marks a significant clinical milestone for the company as it expands its oncology pipeline. By targeting TNBC, Cellectar aims to address a critical unmet medical need in the healthcare sector. This early-stage development is viewed as a positive operational step for the biotech firm, potentially driving long-term value for shareholders. The market will be closely monitoring the initial safety data and efficacy signals from this cohort.